Please login to the form below

Not currently logged in
Email:
Password:

OHE

This page shows the latest OHE news and features for those working in and with pharma, biotech and healthcare.

Pharma must engage on the affordability question, says ABPI

Pharma must engage on the affordability question, says ABPI

Professor Adrian Towse, director of the ABPI funded Office of Health Economics, (OHE) said that one of the main reasons was the need for a return on investment on pharma's

Latest news

  • UK lags behind other countries in use of branded drugs UK lags behind other countries in use of branded drugs

    The research by the Office of Health Economics (OHE) - which receives funding from the drug industry as well as other sources - says that the UK ranked ninth among 13 high-income

  • Pharma R&D costs up tenfold since 1970s Pharma R&D costs up tenfold since 1970s

    According to the OHE, “ it costs more to provide an acceptable return to investors that compensates for the high risks of investing in R&D for new drugs”. ... Collaborations with public organisations that share both the risk and rewards of

  • Jorge Mestre-Ferrandiz to lead Office of Health Economics' consultancy division

    Jorge Mestre-Ferrandiz to lead Office of Health Economics' consultancy division. Takes on newly-created position as OHE Consulting seeks expansion. ... He moved back to UK-based OHE in 2006, however, rejoining as a senior economist.

  • UK to cut spending on new medicines

    UK to cut spending on new medicines. But increased uptake of generics means overall drug spend will rise, says OHE report. ... By 2015 newer products - ie those launched between 2012 and 2015 - will account for less than 2 per cent of NHS spending,

  • Orphan drug legislation hailed as success

    diseases. The assessment, commissioned from the Office of Health Economics (OHE) Consulting, reveals that between 2000 and 2004, R&D investment in rare diseases in Europe increased by more than half;

More from news
Approximately 1 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • Managing real world data governance Managing real world data governance

    In a study conducted by OHE Consulting, funded by Lilly, we analysed the current data governance arrangements in eight countries, and proposed an aspirational governance framework based on these analyses. ... is an economist at the Office of Health

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics